' 
SCIENTIFIC SCORE
Moderately Effective
Based on 16 Researches
8.1
USERS' SCORE
Good
Based on 2 Reviews
8.5
Supplement Facts
Serving Size: 2 Capsules
Amount Per Serving
%DV
Total Carbohydrate
<1g
<1%†
Calcium (from calcium magnesium phytate)
131 mg
10%
Phosphorus (from calcium magnesium phytate)
192 mg
15%
Magnesium (from calcium magnesium phytate)
40 mg
10%
IP-6 (inositol hexaphosphate) (from calcium magnesium phytate)
800 mg
**
Inositol
220 mg
**
Maitake Mushroom Extract standardized to 30% pure D-fraction (9 mg)
30 mg
**
Cat's Claw Extract (bark) standardized to 4% alkaloids (0.4 mg)
10 mg
**
Top Medical Research Studies
9
Maitake polysaccharide shows cancer potential
Polysaccharide isolated from eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cells responses.
High relevance to breast cancer treatment
We investigated how a fungal polysaccharide extracted from maitake mushrooms can impact breast cancer. This treatment approach focuses on myeloid-derived suppressor cells, or MDSCs, which are known to help tumors grow by suppressing the immune response in cancer patients.
Our findings revealed that the maitake polysaccharide, referred to as GFI, significantly reduces the number of MDSCs in the bloodstream and tumor tissue in mice, resulting in slower tumor growth. Interestingly, GFI particularly targets a subset of MDSCs known as PMN-MDSCs, while leaving another type, M-MDSCs, largely unaffected.
We also observed that GFI not only clears out these immune suppressing cells but also revives and activates CD8 T cells, which are crucial for attacking tumors. This dual action enhances the body's natural defenses against cancer, suggesting that GFI could serve as a promising treatment option for breast cancer patients.
Altogether, our study sheds light on an innovative approach to battling breast cancer, further emphasizing the potential of natural compounds derived from mushrooms in cancer therapy.
Our findings revealed that the maitake polysaccharide, referred to as GFI, significantly reduces the number of MDSCs in the bloodstream and tumor tissue in mice, resulting in slower tumor growth. Interestingly, GFI particularly targets a subset of MDSCs known as PMN-MDSCs, while leaving another type, M-MDSCs, largely unaffected.
We also observed that GFI not only clears out these immune suppressing cells but also revives and activates CD8 T cells, which are crucial for attacking tumors. This dual action enhances the body's natural defenses against cancer, suggesting that GFI could serve as a promising treatment option for breast cancer patients.
Altogether, our study sheds light on an innovative approach to battling breast cancer, further emphasizing the potential of natural compounds derived from mushrooms in cancer therapy.
Read More
9
Maitake D-Fraction shows promise in TNBC
Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells.
Direct assessment of maitake benefits
We investigated the potential benefits of D-Fraction, a compound derived from the maitake mushroom, specifically on triple-negative breast cancer (TNBC) cells. TNBC is a challenging subtype of breast cancer with limited treatment options and a high risk of recurrence and metastasis, underscoring the need for innovative therapies.
In our analysis, we observed that D-Fraction appears to reduce the aggressiveness of MDA-MB-231 TNBC cells. This compound helps curb cell proliferation, which is crucial for cancer spread, and lowers their metastatic capabilities. We noted that D-Fraction increases levels of E-cadherin—a protein that supports cell adhesion— and alters the localization of β-catenin, contributing to its potential antitumoral effects.
Additionally, D-Fraction seems to affect the cancer cells' structure, impacting the actin cytoskeleton that plays a role in cell movement and invasion. We found that this mushroom derivative also reduced the activity of key enzymes, MMP-2 and MMP-9, associated with cancer cell invasion. When tested in a xenograft model—where cancer is implanted into animals—D-Fraction demonstrated promising results, indicating a potential therapeutic application.
Overall, our findings suggest that D-Fraction holds promise as a treatment option for aggressive TNBC, marking an exciting development in the search for effective therapies.
In our analysis, we observed that D-Fraction appears to reduce the aggressiveness of MDA-MB-231 TNBC cells. This compound helps curb cell proliferation, which is crucial for cancer spread, and lowers their metastatic capabilities. We noted that D-Fraction increases levels of E-cadherin—a protein that supports cell adhesion— and alters the localization of β-catenin, contributing to its potential antitumoral effects.
Additionally, D-Fraction seems to affect the cancer cells' structure, impacting the actin cytoskeleton that plays a role in cell movement and invasion. We found that this mushroom derivative also reduced the activity of key enzymes, MMP-2 and MMP-9, associated with cancer cell invasion. When tested in a xenograft model—where cancer is implanted into animals—D-Fraction demonstrated promising results, indicating a potential therapeutic application.
Overall, our findings suggest that D-Fraction holds promise as a treatment option for aggressive TNBC, marking an exciting development in the search for effective therapies.
Read More
9
Cat's claw shows potential against breast cancer
The antiproliferative effects of Uncaria tomentosa extracts and fractions on the growth of breast cancer cell line.
Direct evidence of effectiveness
We explored the potential of cat's claw, scientifically known as Uncaria tomentosa, in combating breast cancer. This study aimed to understand how different extracts from this plant affect the growth of breast cancer cells, specifically the MCF7 cell line.
Our findings revealed promising results, showing that the extracts and their refined fractions indeed possess antiproliferative properties. We observed that two specific fractions had noteworthy concentrations needed to inhibit cancer cell growth—10 mg/ml and 20 mg/ml, respectively. At higher concentrations, around 100 mg/ml, these fractions demonstrated an impressive 90% inhibition of cell proliferation.
Overall, the research indicated that cat's claw extracts might be a viable addition to cancer treatments, with their direct impact on breast cancer cells. The promising nature of these extracts raises interesting questions for future studies, specifically about how they could be integrated into existing treatment regimens.
Our findings revealed promising results, showing that the extracts and their refined fractions indeed possess antiproliferative properties. We observed that two specific fractions had noteworthy concentrations needed to inhibit cancer cell growth—10 mg/ml and 20 mg/ml, respectively. At higher concentrations, around 100 mg/ml, these fractions demonstrated an impressive 90% inhibition of cell proliferation.
Overall, the research indicated that cat's claw extracts might be a viable addition to cancer treatments, with their direct impact on breast cancer cells. The promising nature of these extracts raises interesting questions for future studies, specifically about how they could be integrated into existing treatment regimens.
Read More
Most Useful Reviews
8.8
Supports immune system
I purchase this product for my mum, a breast cancer survivor at 86. It effectively builds her immune system and keeps her strong. I truly love it!
Read More
7.5
Noted benefits
Good product. I am using this as part of my regimen for managing breast cancer and have noticed benefits.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 16 Researches
8.1
- All Researches
9
Myo-inositol reverses EMT effects
Myo-Inositol Reverses TGF-β1-Induced EMT in MCF-10A Non-Tumorigenic Breast Cells.
High relevance to breast cancer
We explored how myo-inositol impacts breast cells, particularly in the context of a process called Epithelial-Mesenchymal Transition (EMT). This process, often triggered by factors like transforming growth factor beta 1 (TGF-β1), leads to changes in cells that can contribute to cancer progression.
Our study focused on non-tumorigenic MCF-10A breast cells, where we observed a remarkable transformation when these cells were exposed to TGF-β1. The cells lost their usual tight connections and took on a more flexible, mesenchymal shape, which is a hallmark of EMT.
However, when we applied myo-inositol, we saw an impressive reversal of these changes. The presence of myo-inositol helped restore the important cell connection proteins (E-cadherin-β-catenin complexes) and encouraged the re-expression of epithelial markers. This shift not only limited the cells' invasive capabilities but also reduced the release of proteins associated with cancer spread.
Our findings indicate that myo-inositol may offer a promising avenue for improving breast cancer treatment by counteracting the effects of EMT. It's encouraging to think about how this simple compound could play a critical role in fighting cancer progression.
Our study focused on non-tumorigenic MCF-10A breast cells, where we observed a remarkable transformation when these cells were exposed to TGF-β1. The cells lost their usual tight connections and took on a more flexible, mesenchymal shape, which is a hallmark of EMT.
However, when we applied myo-inositol, we saw an impressive reversal of these changes. The presence of myo-inositol helped restore the important cell connection proteins (E-cadherin-β-catenin complexes) and encouraged the re-expression of epithelial markers. This shift not only limited the cells' invasive capabilities but also reduced the release of proteins associated with cancer spread.
Our findings indicate that myo-inositol may offer a promising avenue for improving breast cancer treatment by counteracting the effects of EMT. It's encouraging to think about how this simple compound could play a critical role in fighting cancer progression.
Read More
9
Maitake polysaccharide shows cancer potential
Polysaccharide isolated from eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cells responses.
High relevance to breast cancer treatment
We investigated how a fungal polysaccharide extracted from maitake mushrooms can impact breast cancer. This treatment approach focuses on myeloid-derived suppressor cells, or MDSCs, which are known to help tumors grow by suppressing the immune response in cancer patients.
Our findings revealed that the maitake polysaccharide, referred to as GFI, significantly reduces the number of MDSCs in the bloodstream and tumor tissue in mice, resulting in slower tumor growth. Interestingly, GFI particularly targets a subset of MDSCs known as PMN-MDSCs, while leaving another type, M-MDSCs, largely unaffected.
We also observed that GFI not only clears out these immune suppressing cells but also revives and activates CD8 T cells, which are crucial for attacking tumors. This dual action enhances the body's natural defenses against cancer, suggesting that GFI could serve as a promising treatment option for breast cancer patients.
Altogether, our study sheds light on an innovative approach to battling breast cancer, further emphasizing the potential of natural compounds derived from mushrooms in cancer therapy.
Our findings revealed that the maitake polysaccharide, referred to as GFI, significantly reduces the number of MDSCs in the bloodstream and tumor tissue in mice, resulting in slower tumor growth. Interestingly, GFI particularly targets a subset of MDSCs known as PMN-MDSCs, while leaving another type, M-MDSCs, largely unaffected.
We also observed that GFI not only clears out these immune suppressing cells but also revives and activates CD8 T cells, which are crucial for attacking tumors. This dual action enhances the body's natural defenses against cancer, suggesting that GFI could serve as a promising treatment option for breast cancer patients.
Altogether, our study sheds light on an innovative approach to battling breast cancer, further emphasizing the potential of natural compounds derived from mushrooms in cancer therapy.
Read More
9
Maitake D-Fraction shows promise in TNBC
Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells.
Direct assessment of maitake benefits
We investigated the potential benefits of D-Fraction, a compound derived from the maitake mushroom, specifically on triple-negative breast cancer (TNBC) cells. TNBC is a challenging subtype of breast cancer with limited treatment options and a high risk of recurrence and metastasis, underscoring the need for innovative therapies.
In our analysis, we observed that D-Fraction appears to reduce the aggressiveness of MDA-MB-231 TNBC cells. This compound helps curb cell proliferation, which is crucial for cancer spread, and lowers their metastatic capabilities. We noted that D-Fraction increases levels of E-cadherin—a protein that supports cell adhesion— and alters the localization of β-catenin, contributing to its potential antitumoral effects.
Additionally, D-Fraction seems to affect the cancer cells' structure, impacting the actin cytoskeleton that plays a role in cell movement and invasion. We found that this mushroom derivative also reduced the activity of key enzymes, MMP-2 and MMP-9, associated with cancer cell invasion. When tested in a xenograft model—where cancer is implanted into animals—D-Fraction demonstrated promising results, indicating a potential therapeutic application.
Overall, our findings suggest that D-Fraction holds promise as a treatment option for aggressive TNBC, marking an exciting development in the search for effective therapies.
In our analysis, we observed that D-Fraction appears to reduce the aggressiveness of MDA-MB-231 TNBC cells. This compound helps curb cell proliferation, which is crucial for cancer spread, and lowers their metastatic capabilities. We noted that D-Fraction increases levels of E-cadherin—a protein that supports cell adhesion— and alters the localization of β-catenin, contributing to its potential antitumoral effects.
Additionally, D-Fraction seems to affect the cancer cells' structure, impacting the actin cytoskeleton that plays a role in cell movement and invasion. We found that this mushroom derivative also reduced the activity of key enzymes, MMP-2 and MMP-9, associated with cancer cell invasion. When tested in a xenograft model—where cancer is implanted into animals—D-Fraction demonstrated promising results, indicating a potential therapeutic application.
Overall, our findings suggest that D-Fraction holds promise as a treatment option for aggressive TNBC, marking an exciting development in the search for effective therapies.
Read More
9
Maitake mushroom shows promise against breast cancer
Grifola frondosa polysaccharides induce breast cancer cell apoptosis via the mitochondrial-dependent apoptotic pathway.
Highly relevant to breast cancer treatment
We examined the potential of maitake mushroom polysaccharides, known for their medicinal properties, to combat breast cancer. Our focus was on how these compounds affect breast cancer cells, specifically in the widely studied MCF-7 and MDA-MB-231 cancer cell lines, as well as in tumor models grown in mice.
The findings were promising. We observed that maitake mushroom extract significantly reduced cell viability, which indicates that it may effectively kill cancer cells. Additionally, there was an increase in apoptotic rates—essentially, the rate at which cancer cells undergo programmed cell death. This process was linked to mitochondrial dysfunction, a key factor in cancer progression.
We noted specific changes in the cellular environment as well. In cells treated with the mushroom extract, levels of proteins that promote cell death increased while levels of proteins that help cancer cells survive decreased. This molecular shift supports the idea that maitake mushroom polysaccharides could play a crucial role in cancer treatment.
Furthermore, the extract inhibited certain important signaling pathways related to cell growth and survival. In the live tumor models, we confirmed the anti-cancer effects of maitake polysaccharides by observing the inhibited growth of breast cancer tumors. Overall, our research contributes to the understanding of how maitake mushroom may offer new avenues for breast cancer therapies.
The findings were promising. We observed that maitake mushroom extract significantly reduced cell viability, which indicates that it may effectively kill cancer cells. Additionally, there was an increase in apoptotic rates—essentially, the rate at which cancer cells undergo programmed cell death. This process was linked to mitochondrial dysfunction, a key factor in cancer progression.
We noted specific changes in the cellular environment as well. In cells treated with the mushroom extract, levels of proteins that promote cell death increased while levels of proteins that help cancer cells survive decreased. This molecular shift supports the idea that maitake mushroom polysaccharides could play a crucial role in cancer treatment.
Furthermore, the extract inhibited certain important signaling pathways related to cell growth and survival. In the live tumor models, we confirmed the anti-cancer effects of maitake polysaccharides by observing the inhibited growth of breast cancer tumors. Overall, our research contributes to the understanding of how maitake mushroom may offer new avenues for breast cancer therapies.
Read More
9
Maitake extract shows cancer prevention
Maitake Pro4X has anti-cancer activity and prevents oncogenesis in BALBc mice.
Relevant for breast cancer treatment
We conducted an investigation into the potential of Maitake mushroom extract, specifically the D-Fraction Pro4X, to prevent breast cancer. Our study involved 25 female BALBc mice, which were administered either the Maitake D-Fraction Pro4X or a standard Maitake extract for 15 days before being implanted with tumor cells to induce breast cancer.
Throughout this period, we monitored the impact of these treatments on tumor development and overall health. Remarkably, we found that the mice treated with Maitake D-Fraction Pro4X experienced over 60% reduction in breast cancer development. In contrast, the standard Maitake extract was only able to prevent cancer development by about 26%.
Our findings suggest that Maitake D-Fraction Pro4X not only helps to block the onset of breast cancer but also reduces tumor growth, inhibits invasiveness, and enhances overall survival rates in these mice. This indicates a significant potential for Maitake mushroom extracts in cancer prevention strategies.
Throughout this period, we monitored the impact of these treatments on tumor development and overall health. Remarkably, we found that the mice treated with Maitake D-Fraction Pro4X experienced over 60% reduction in breast cancer development. In contrast, the standard Maitake extract was only able to prevent cancer development by about 26%.
Our findings suggest that Maitake D-Fraction Pro4X not only helps to block the onset of breast cancer but also reduces tumor growth, inhibits invasiveness, and enhances overall survival rates in these mice. This indicates a significant potential for Maitake mushroom extracts in cancer prevention strategies.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Supports immune system
I purchase this product for my mum, a breast cancer survivor at 86. It effectively builds her immune system and keeps her strong. I truly love it!
7.5
Noted benefits
Good product. I am using this as part of my regimen for managing breast cancer and have noticed benefits.
